Αποτελέσματα Αναζήτησης
Provide real-time access to data for patients taking TYSABRI. Maintain compliance with the TOUCH Prescribing Program. Reduce administrative burden/paperwork for prescribers and infusion sites. Streamline communication to/from prescribers and infusion sites. TOUCH On-Line is accessed with a secure username and password.
The TOUCH Prescribing Program is designed to: Inform prescribers, infusion center healthcare providers, and patients about the risk of progressive multifocal leukoencephalopathy (PML) associated with TYSABRI including the increased risk of PML with treatment duration and prior immunosuppressant use.
• TOUCH On-Line is a web-based tool designed to: – Provide real-time access to TYSABRI patient data – Maintain compliance with the TOUCH Prescribing Program – Reduce administrative burden/paperwork for prescribers and infusion sites • TOUCH On-Line is accessed with secure username and password How the program works
1 Απρ 2014 · Tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: Patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (DMT) (for exceptions and information about ...
1 Φεβ 2008 · Q. Will my insurance cover the cost of Tysabri? A. Insurance coverage for Tysabri will vary based on an individual’s plan. The actual price you pay may vary based on your health plan coverage, as well as where you receive Tysabri. For patients enrolled in the TOUCH Prescribing Program, Biogen Idec can provide assistance in
TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML). When starting and continuing treatment with TYSABRI, it is important to discuss with your doctor whether the expected benefit of TYSABRI is enough to outweigh this risk. IMPORTANT SAFETY INFORMATION What is the most important information I should know about TYSABRI?
TYSABRI® is indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn’s disease with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of TNF-α.
